Skip to main content
Erschienen in: International Urology and Nephrology 4/2008

01.12.2008 | Urology-Original Paper

Impact of preoperative antiandrogen medication and nerve-sparing surgery on the outcome of radical prostatectomy

verfasst von: J. Hodzic, P. Jedrusik, T. Reckwitz, H.-J. Knopf, K. Golka

Erschienen in: International Urology and Nephrology | Ausgabe 4/2008

Einloggen, um Zugang zu erhalten

Abstract

Objectives

Radical prostatectomy in antiandrogen-medicated patients, as well as nerve-sparing surgery, has increased within recent years. We investigated the impact of antiandrogen medication on loss of blood and of nerve-sparing surgery on continence and potency.

Methods

A total of 401 men who underwent radical prostatectomy between January 1995 and September 1999 at our clinic were asked about antiandrogenic medication prior to radical prostatectomy and about daily life activities, overall satisfaction, voiding ability, and sexual activities. Consumption of erythrocyte concentrates and cryoprecipitated plasma was taken from the records.

Results

The average follow-up was 36 months. Seventy-two percent (n = 289) of our patients replied. Sixty-seven men (23%) who replied to our questionnaire had received antiandrogen medication prior to radical prostatectomy. In 53 (18%) of the men, the nerve-sparing technique was used. In antiandrogen-medicated patients, we observed a significantly elevated consumption of erythrocyte concentrates (antiandrogen-medicated 0.93, not antiandrogen-medicated 0.44; P = 0.013) and of cryoprecipitated plasma (antiandrogen-medicated 0.39, not antiandrogen-medicated 0.08; P = 0.010). Patients who underwent the nerve-sparing technique reported better results in daily life activities, general health status, International Prostate Symptom Score (IPSS), and continence.

Conclusion

Our results point to a higher quality of life in patients who had undergone nerve-sparing surgery.
Literatur
2.
Zurück zum Zitat RKI Robert-Koch-Institut (2004) EUCAN 98. In: Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland Häufigkeiten und Trends 4. überarbeitete, aktualisierte Ausgabe Saarbrücken, pp 64–67 RKI Robert-Koch-Institut (2004) EUCAN 98. In: Arbeitsgemeinschaft Bevölkerungsbezogener Krebsregister in Deutschland. Krebs in Deutschland Häufigkeiten und Trends 4. überarbeitete, aktualisierte Ausgabe Saarbrücken, pp 64–67
3.
Zurück zum Zitat Quinn M, Bapp P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I. International comparisons. BJU Int 90:162–173PubMedCrossRef Quinn M, Bapp P (2002) Patterns and trends in prostate cancer incidence, survival, prevalence and mortality. Part I. International comparisons. BJU Int 90:162–173PubMedCrossRef
4.
Zurück zum Zitat Noldus J, Graefen M, Haese A et al (2000) Stage migration in clinically localized prostate cancer. Eur Urol 38: 74–78PubMedCrossRef Noldus J, Graefen M, Haese A et al (2000) Stage migration in clinically localized prostate cancer. Eur Urol 38: 74–78PubMedCrossRef
5.
Zurück zum Zitat Reiner WG, Scott WW, Eggleston JC, Walsh PC (1979) Long-term survival after hormonal therapy for stage D prostatic cancer. J Urol 122:183–184PubMed Reiner WG, Scott WW, Eggleston JC, Walsh PC (1979) Long-term survival after hormonal therapy for stage D prostatic cancer. J Urol 122:183–184PubMed
6.
Zurück zum Zitat Walsh PC, Donker PJ (1982) Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 128:492–497PubMed Walsh PC, Donker PJ (1982) Impotence following radical prostatectomy: insight into etiology and prevention. J Urol 128:492–497PubMed
7.
Zurück zum Zitat Holmberg L, Bill-Axelson A, Helgesen F et al (2002) Scandinavian Prostatic Cancer Group Study number 4: a randomised trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781–789PubMedCrossRef Holmberg L, Bill-Axelson A, Helgesen F et al (2002) Scandinavian Prostatic Cancer Group Study number 4: a randomised trial comparing radical prostatectomy with watchful waiting in early prostate cancer. N Engl J Med 347:781–789PubMedCrossRef
8.
Zurück zum Zitat Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154–179PubMedCrossRef Hellerstedt BA, Pienta KJ (2002) The current state of hormonal therapy for prostate cancer. CA Cancer J Clin 52:154–179PubMedCrossRef
9.
Zurück zum Zitat Prezioso D, Lotti T, Polito M, Montironi R (2004) Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int 72:189–195PubMedCrossRef Prezioso D, Lotti T, Polito M, Montironi R (2004) Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int 72:189–195PubMedCrossRef
10.
Zurück zum Zitat Wirth M, Tyrrell C, Delaere K et al ‘Casodex’ Early Prostate Cancer Trialists’ Group (2005) Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer Prostatic Dis 8:194–200 Wirth M, Tyrrell C, Delaere K et al ‘Casodex’ Early Prostate Cancer Trialists’ Group (2005) Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme. Prostate Cancer Prostatic Dis 8:194–200
11.
Zurück zum Zitat Jonler M, Madsen FA, Rhodes PR et al (1996) A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy. Urology 48:433–440PubMedCrossRef Jonler M, Madsen FA, Rhodes PR et al (1996) A prospective study of quantification of urinary incontinence and quality of life in patients undergoing radical retropubic prostatectomy. Urology 48:433–440PubMedCrossRef
12.
Zurück zum Zitat Jedrusik P, Schulze H, Claussen CD, Golka K (2005) Low-cost data transfer from a questionnaire to standard software using a barcode pen. Behav Res Methods 37:127–132PubMed Jedrusik P, Schulze H, Claussen CD, Golka K (2005) Low-cost data transfer from a questionnaire to standard software using a barcode pen. Behav Res Methods 37:127–132PubMed
13.
Zurück zum Zitat Litwiller SE, Djavan B, Kolpukh BV et al (1995) Radical retropubic prostatectomy for localised carcinoma of the prostate in a large metropolitan hospital. Changing trends over a 10-year-period (1984–1994). Dallas Outcome Research Group for Urological Diseases. Urology 45:813–822 Litwiller SE, Djavan B, Kolpukh BV et al (1995) Radical retropubic prostatectomy for localised carcinoma of the prostate in a large metropolitan hospital. Changing trends over a 10-year-period (1984–1994). Dallas Outcome Research Group for Urological Diseases. Urology 45:813–822
14.
Zurück zum Zitat Epstein JI, Chan DW, Sokoll LJ et al (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160:2407–2411PubMedCrossRef Epstein JI, Chan DW, Sokoll LJ et al (1998) Nonpalpable stage T1c prostate cancer: prediction of insignificant disease using free/total prostate specific antigen levels and needle biopsy findings. J Urol 160:2407–2411PubMedCrossRef
15.
Zurück zum Zitat Noldus J, Graefen M, Hammerer P et al (1998) Entwicklung der Tumorselektion anhand des pathologischen Stadiums beim klinischen lokalisierten Prostatakarzinom. Urologe A 37:195–198PubMedCrossRef Noldus J, Graefen M, Hammerer P et al (1998) Entwicklung der Tumorselektion anhand des pathologischen Stadiums beim klinischen lokalisierten Prostatakarzinom. Urologe A 37:195–198PubMedCrossRef
16.
Zurück zum Zitat Thompson IM, Middelton RG, Optenberg SA et al (1999) Have complication rates decreased after treatment for localized prostate cancer? J Urol 162:107–112PubMedCrossRef Thompson IM, Middelton RG, Optenberg SA et al (1999) Have complication rates decreased after treatment for localized prostate cancer? J Urol 162:107–112PubMedCrossRef
17.
Zurück zum Zitat Lu-Yao GL, Yao SL (1997) Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 349:906–910PubMedCrossRef Lu-Yao GL, Yao SL (1997) Population-based study of long-term survival in patients with clinically localised prostate cancer. Lancet 349:906–910PubMedCrossRef
18.
Zurück zum Zitat Fowler FJ Jr, Barry MJ, Lu-Yao G et al (1993) Patient-reported complications and follow-up treatment after radical prostatectomy. The national Medicare Experience: 1988–1990 (updated 1993). Urology 42:622–629 Fowler FJ Jr, Barry MJ, Lu-Yao G et al (1993) Patient-reported complications and follow-up treatment after radical prostatectomy. The national Medicare Experience: 1988–1990 (updated 1993). Urology 42:622–629
19.
Zurück zum Zitat Eastham JA, Kattan UW, Rogers E et al (1996) Risk factors for urinary incontinence after radical prostatectomy. J Urol 156:1707–1713PubMedCrossRef Eastham JA, Kattan UW, Rogers E et al (1996) Risk factors for urinary incontinence after radical prostatectomy. J Urol 156:1707–1713PubMedCrossRef
20.
Zurück zum Zitat Walsh PC (2000) Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. J Urol 164:242PubMed Walsh PC (2000) Patient-reported urinary continence and sexual function after anatomic radical prostatectomy. J Urol 164:242PubMed
21.
Zurück zum Zitat Catalona WJ, Basler JW (1993) Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. J Urol 150:905–907PubMed Catalona WJ, Basler JW (1993) Return of erections and urinary continence following nerve sparing radical retropubic prostatectomy. J Urol 150:905–907PubMed
22.
Zurück zum Zitat Geary ES, Dendinger TE, Freiha FS, Stamey TA (1995) Nerve sparing radical prostatectomy: a different view. J Urol 154:145–149PubMedCrossRef Geary ES, Dendinger TE, Freiha FS, Stamey TA (1995) Nerve sparing radical prostatectomy: a different view. J Urol 154:145–149PubMedCrossRef
23.
Zurück zum Zitat Noldus J, Michl U, Graefen M et al (2001) Die nerverhaltende radikale retropubische Prostatektomie. Urologe A 40:102–106PubMedCrossRef Noldus J, Michl U, Graefen M et al (2001) Die nerverhaltende radikale retropubische Prostatektomie. Urologe A 40:102–106PubMedCrossRef
Metadaten
Titel
Impact of preoperative antiandrogen medication and nerve-sparing surgery on the outcome of radical prostatectomy
verfasst von
J. Hodzic
P. Jedrusik
T. Reckwitz
H.-J. Knopf
K. Golka
Publikationsdatum
01.12.2008
Verlag
Springer Netherlands
Erschienen in
International Urology and Nephrology / Ausgabe 4/2008
Print ISSN: 0301-1623
Elektronische ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-008-9372-5

Weitere Artikel der Ausgabe 4/2008

International Urology and Nephrology 4/2008 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.